Information Provided By: 
Fly News Breaks for October 27, 2016
SRPT
Oct 27, 2016 | 13:42 EDT
After management of Sarepta Therapeutics guided that reimbursement typically takes 30-90 days, Piper Jaffray analyst Edward Tenthoff cut his U.S. Exondys51 forecast to $4.5M from $21.5M in Q4 and to $274M from $330M in 2017. The analyst continues to project peak U.S. sales of greater than $500M. He reiterates an Overweight rating on shares of Sarepta with a $68 price atregt following the company's Q3 results. The stock is down 9%, or $3.84, to $40.70 in afternoon trading.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
